Homepage Top Section2

Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody. It targets both GPRC5D, a novel drug target that is on some normal cells but overexpressed

Cilta-cel is a BCMA-directed and genetically modified autologous T-cell immunotherapy that involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR), which detects

The regulatory acceptance of application for marketing authorisation of tislelizumab is to treat first-line unresectable or metastatic HCC patients. The humanised IgG4 anti-PD-1 monoclonal antibody tislelizumab has been

The company submitted the vaccine candidate to prevent meningococcal disease, which is caused by the most common serogroups, in individuals aged 10 to 25 years. MenABCWY combines the

The company has also received additional funding from JLS Fund, Gron Ventures, Alumni Ventures, Palo Santo, Satori Capital, Negev Capital, and Route 66. It intends to use the

With a differentiated mechanism of action, momelotinib has inhibitory ability along three important signalling pathways, Janus kinase (JAK) 1, and JAK2 and activin A receptor type I (ACVR1).

The financing round was co-led by ORI Capital, Longitude Capital and Decheng Capital. It has also seen participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge

Nearly 1,600 people in England alone are expected to benefit from the immunotherapy drug. Previously, the drug was available for a small group of people with advanced TNBC

The new, oral formulation of CD/LD extended-release capsules, IPX203 features immediate-release granules and extended-release beads. Findings from the pivotal Phase III RISE-PD clinical trial showed that the extended-release